BIO-Europe 2009 Profiles

VIENNA--(BUSINESS WIRE)--BIO-Europe 2009 takes place November 2-4, 2009 at the Messe Wien Exhibition & Congress Center in Vienna.

BIO-Europe 2009 breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Listed below are BIO-Europe 2009 profiles.

Company:	Addex Pharmaceuticals
Ticker Symbol & Exchange:	SIX: ADXN
Media Contact:	Chris Maggos
Phone:	41 79 367 6254
E-mail:	[e-mail]
Web:	www.addexpharma.com
Addex Pharmaceuticals discovers and develops allosteric modulators for human health. Allosteric modulators are a different kind of orally available small molecule therapeutic agent, which we believe will offer a competitive advantage over classical drugs. The lead product in our pipeline, ADX10059, has achieved clinical proof of concept and is completing Phase IIb trials in GERD (e.g. heartburn) and, separately, migraine headache. ADX10059 is a first-in-class mGluR5 inhibitor, a therapeutic strategy that also is being pursued for multiple indications by large pharma competitors.
Our technology and products already have proven their value through our relationships with four of the top 10 pharmaceutical companies in the world. We have drug development agreements with Ortho-McNeil-Janssen and Merck & Co., Inc. Also, GlaxoSmithKline and Roche have equity investments.
Company:	Angiochem
Media Contact:	Gina Nugent, Yates Associates
Phone:	617-460-3579
E-mail:	[e-mail]
Web:	www.angiochem.com
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier (BBB) to treat brain diseases. The company’s proprietary Engineered Peptide Compounds (EPiC) technology creates drugs that cross the BBB and reach therapeutic concentration in the brain, by harnessing naturally-occurring receptors on the surface of the BBB. Angiochem’s lead product candidate, ANG1005 is in two separate Phase 1/2 clinical studies in patients with brain cancers and cancer metastases. Additionally, Angiochem is developing a deep and broad product pipeline, including small and large molecules, for the potential treatment of a wide range of CNS diseases, including neurodegenerative and metabolic diseases, brain cancer, psychiatric disorders and many others.
Company:	BIA Separations GmbH
Media Contact:	Gregor Krajnc
Phone:	386 1 426 5649
E-mail:	[e-mail]
Web:	www.monoliths.com
BIA Separations is a developer and producer of patented innovative monolith based chromatographic supports (CIM Convective Interaction Media®) offering dramatic cost savings in biopharmaceutical development and production due to its effects on speed, productivity and preservation of biologic material during the stages of production. The unparalleled know-how, the development and production experiences and sustainable investment levels are able to propel CIM® Technology to industry standard for biomolecule purification. BIA Separations is looking to increase its presence in the laboratory market by partnering with OEMs as well as to attract venture capital that would assure the company’s continuous growth.
Company:	mtm laboratories, AG
Media Contact:	Bob Silverman, CEO
Phone:	1-508-366-8334
E-mail:	[e-mail]
Web:	www.mtmlabs.com
mtm laboratories is a certified developer and manufacturer of In-vitro Diagnostics for screening and diagnosis of cervical cancer with products marketed world-wide. The privately held company is headquartered in Heidelberg, Germany, with subsidiaries in Westborough (MA), USA, France, Spain, Italy and Japan.
Cervical cancer screening represents the largest existing screening market in oncology, and mtm's products are targeted to address significant unmet clinical needs. The biomarker-based diagnostic assays have been demonstrated to provide excellent sensitivity and specificity profiles as compared to conventional screening methods for identifying cervical pre-cancerous and cancerous lesions. The products are based on antibodies to detect p16, which is a well defined marker for cervical disease. The company holds an extensive patent position around this marker and its products.
Company:	NovaBiotics Ltd
Media Contact:	Diane Stewart, Buchanan Communications
Phone:	0131 226 6150
E-mail:	[e-mail]
Web:	http://www.novabiotics.co.uk
NovaBiotics is a clinical stage anti-infectives drug discovery company based in Aberdeen, UK. Their lead product, Novexatin®, is a topical treatment for fungal nail infection which is expected to complete phase IIa of clinical evaluation before the end of 2009.
Fungal nail infections affect more than 12% of the world’s population and provide a global market worth approximately $5 billion.
NovaBiotics’ product pipeline and technology platform comprise antifungal peptides against potentially life-threatening systemic yeast infections and antibacterial peptides for serious respiratory, systemic, and dermal infections.
The company’s Luminaderm® range of compounds has applications across consumer healthcare and cosmetic products.
Company:	Oncolytics Biotech Inc.
Ticker Symbol & Exchange:	TSX: ONC, NASDAQ; ONCY
Media Contact:	Cathy Ward
Phone:	403.670.7370
E-mail:	[e-mail]
Web:	www.oncolyticsbiotech.com
Oncolytics Biotech® Inc. is conducting clinical trials in the U.S. and the U.K. with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes eight Phase I/II or Phase II human trials examining REOLYSIN alone or in combination with chemotherapy.
This clinical program is designed to identify targets for late-stage registration trials with REOLYSIN, the first of which is planned to be a Phase III combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-failed head and neck cancers.
Company:	Pharmatest Services Ltd
Stand:	41
Media Contact:	Rami Kakonen
Phone:	35822784701
E-mail:	[e-mail]
Web:	http://www.pharmatest.fi
Pharmatest Services offers a set of fast, clinically predictive and cost-effective tools for preclinical lead validation and efficacy testing of drug compounds against osteoporosis, cancer-induced bone disease and osteoarthritis.
Our unique in vitro bone cell assays (osteoclast assays for antiresorptive compounds and osteoblast assays for anabolic compounds) are perfect for selecting most potent drug candidates for further testing in our animal models.
These include models of primary and secondary osteoporosis, systemic models of cancer bone metastasis and osteoarthritis. The primary osteoporosis animal models can be performed according to FDA/EMEA guidelines, allowing the use of the results in drug approval process.
Company:	Rentschler Biotechnologie GmbH
Stand:	73
Media Contact:	Friederike Braun
Phone:	49 7392 701 555
E-mail:	[e-mail]
Web:	www.rentschler-biotechnologie.de/x9d
Rentschler Biotechnologie is an international full-service contract manufacturer with more than 30 years of experience in the development, production and approval of biopharmaceuticals compliant with international GMP standards. Rentschler Biotechnologies’ full-service competence allows maximum flexibility when reacting to customers’ needs and requirements for rapid and reliable project success. Short development periods, optimal time to market and the highest standards of quality and efficiency are guaranteed.
GMP certified services:
--- Cell Line and Process Development
--- Production of Active Pharmaceutical Ingredients (API)
--- Fill and Finish
--- Analytics and Quality Control
--- Regulatory Affairs
--- Quality Assurance
--- Corporate Project Management

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.